This study focuses on Duchenne Muscular Dystrophy, a genetic condition that causes progressive muscle weakness and primarily affects males. The study will test a new medication called ENTR-601-45, which is given through intravenous infusion (delivered directly into a vein). Some participants will receive the study medication while others will receive a placebo (inactive substance).

The purpose of this research is to determine if ENTR-601-45 is safe and well-tolerated in people with Duchenne Muscular Dystrophy who have a specific genetic change that can be treated by skipping a part of the gene called exon 45. The study is divided into two parts, with the first part testing different dose levels of the medication to understand how it works in the body and how safe it is.

During the study, participants will receive regular infusions of either ENTR-601-45 or placebo. The research team will monitor the participants’ health through various tests, including muscle tissue samples to see how the treatment affects the muscles. Neither the participants nor the study doctors will know who is receiving the actual medication or the placebo during the study period.